Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • About
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “Myelodysplastic Syndrome With Gene Mutation”

55 trials

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 55 results

Not applicableStudy completedNCT03894852
What this trial is testing

SRSF2 Gene Mutation in Patients With t-MDS/AML

Who this might be right for
Therapy Related Myelodysplastic Syndrome and Therapy Related Acute Myeloid Leukemia
Zeinab Albadry Mohammed Zahran 139
Large-scale testing (Phase 3)Active Not RecruitingNCT03173248
What this trial is testing

Study of AG-120 (Ivosidenib) vs. Placebo in Combination With Azacitidine in Participants With Previously Untreated Acute Myeloid Leukemia With an IDH1 Mutation

Who this might be right for
Newly Diagnosed Acute Myeloid Leukemia (AML)Untreated AMLAML Arising From Myelodysplastic Syndrome (MDS)+1 more
Institut de Recherches Internationales Servier 146
Testing effectiveness (Phase 2)Looking for participantsNCT04140487
What this trial is testing

Azacitidine, Venetoclax, and Gilteritinib in Treating Patients With Recurrent/Refractory FLT3-Mutated Acute Myeloid Leukemia, Chronic Myelomonocytic Leukemia, or High-Risk Myelodysplastic Syndrome/Myeloproliferative Neoplasm

Who this might be right for
Recurrent Acute Myeloid LeukemiaRecurrent Chronic Myelomonocytic LeukemiaRecurrent Myelodysplastic/Myeloproliferative Neoplasm+3 more
M.D. Anderson Cancer Center
Testing effectiveness (Phase 2)Looking for participantsNCT04493164
What this trial is testing

CPX-351 and Ivosidenib for the Treatment of IDH1 Mutated Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome

Who this might be right for
Acute Myeloid Leukemia With Gene MutationsMyelodysplastic SyndromeMyeloproliferative Neoplasm+2 more
M.D. Anderson Cancer Center 30
Not applicableLooking for participantsNCT07019155
What this trial is testing

Study of Individuals and Families With Aberrations in DDX41 or Similar Cancer Predisposition Variants

Who this might be right for
Germline MutationMyelodysplastic SyndromesAcute Myeloid Leukemia
National Cancer Institute (NCI) 510
Very early researchEnded earlyNCT03272633
What this trial is testing

Irradiated Donor Cells Following Stem Cell Transplant in Controlling Cancer in Patients With Hematologic Malignancies

Who this might be right for
Acute Lymphoblastic LeukemiaAcute Myeloid Leukemia in RemissionHematopoietic Cell Transplantation Recipient+16 more
Rutgers, The State University of New Jersey 2
Not applicableLooking for participantsNCT07143669
What this trial is testing

Screening Study for KIT D816V Mutated Mast Cell Disease in Select Populations

Who this might be right for
Clonal Mast Cell DiseaseKIT D816V MutationSuspected KITD816V Mutated Clonal Mast Cell Disease
Blueprint Medicines Corporation 450
Not applicableStudy completedNCT02487069
What this trial is testing

Allo-HSCT With Alternative Donor in Treatment of Hematologic Malignancy

Who this might be right for
Acute LeukemiaChronic Myeloid LeukemiaMyelodysplastic Syndrome
Nanfang Hospital, Southern Medical University 876
Testing effectiveness (Phase 2)Study completedNCT05282459
What this trial is testing

Enasidenib in MDS &Non-proliferative Chronic Myelomonocytic Leukemia w/o IDH2 Mutation

Who this might be right for
LeukemiaLeukemia, MyeloidMonocytic Leukemia
Stanford University 17
Not applicableLooking for participantsNCT05983991
What this trial is testing

Study for Characterisation of Predictive Parameters of Clonal Evolution in Subjects With GATA2 Germline Mutation

Who this might be right for
GATA2 Gene Mutation
Institut Claudius Regaud 150
Early research (Phase 1)Looking for participantsNCT06543381
What this trial is testing

Olutasidenib for the Treatment of Patients With IDH1 Mutated AML, MDS or CMML After Donor Hematopoietic Cell Transplant

Who this might be right for
Acute Myeloid LeukemiaChronic Myelomonocytic LeukemiaMyelodysplastic Syndrome
City of Hope Medical Center 15
Testing effectiveness (Phase 2)Looking for participantsNCT06778187
What this trial is testing

Oral-ATO for TP53-mutated Myeloid Malignancies

Who this might be right for
Acute Myeloid LeukemiaMyelodysplastic NeoplasmChronic Myelomonocytic Leukemia+2 more
The University of Hong Kong 30
Testing effectiveness (Phase 2)Looking for participantsNCT05735717
What this trial is testing

MT2021-08T Cell Receptor Alpha/Beta Depletion PBSC Transplantation for Heme Malignancies

Who this might be right for
Hematologic MalignancyAcute LeukemiaRemission+19 more
Masonic Cancer Center, University of Minnesota 70
Testing effectiveness (Phase 2)Active Not RecruitingNCT06268574
What this trial is testing

Safety and Efficacy of RVU120 for Treatment of Relapsed/Refractory AML

Who this might be right for
Acute Myeloid Leukemia (AML)High-risk Myelodysplastic Syndrome
Ryvu Therapeutics SA 94
Early research (Phase 1)Study completedNCT06100900
What this trial is testing

Dose Escalation of BCX10013 in Participants with Paroxysmal Nocturnal Hemoglobinuria (PNH)

Who this might be right for
Paroxysmal Nocturnal Hemoglobinuria
BioCryst Pharmaceuticals 8
Testing effectiveness (Phase 2)UnknownNCT03588078
What this trial is testing

Study of the Safety and Efficacy of APR-246 in Combination With Azacitidine

Who this might be right for
Myelodysplastic Syndrome With Gene MutationAcute Myeloid Leukemia With Gene MutationsMyeloproliferative Neoplasm+1 more
Groupe Francophone des Myelodysplasies 53
Testing effectiveness (Phase 2)Looking for participantsNCT03383575
What this trial is testing

Azacitidine and Enasidenib in Treating Patients With IDH2-Mutant Myelodysplastic Syndrome

Who this might be right for
Acute Myeloid LeukemiaBlasts 20-30 Percent of Bone Marrow Nucleated CellsChronic Myelomonocytic Leukemia+4 more
M.D. Anderson Cancer Center 63
Not applicableEnded earlyNCT01463410
What this trial is testing

Accuracy Testing of the Chromosomal Aberration and Gene Mutation Markers of the AMLProfiler

Who this might be right for
Acute Myeloid Leukemia (AML)Acute Promyelocytic Leukemia (APL)Refractory Anemia With Excess of Blasts (RAEB)
Skyline Diagnostics BV 264
Early research (Phase 1)Active Not RecruitingNCT02632708
What this trial is testing

Safety Study of AG-120 or AG-221 in Combination With Induction and Consolidation Therapy in Participants With Newly Diagnosed Acute Myeloid Leukemia (AML) With an IDH1 and/or IDH2 Mutation

Who this might be right for
Newly Diagnosed Acute Myeloid Leukemia (AML)Untreated AMLAML Arising From Myelodysplastic Syndrome (MDS)+2 more
Institut de Recherches Internationales Servier 153
Early research (Phase 1)Study completedNCT02492737
What this trial is testing

Study of Orally Administered AG-881 in Patients With Advanced Hematologic Malignancies With an IDH1 and/or IDH2 Mutation

Who this might be right for
Acute Myeloid Leukemia (AML)Myelodysplastic SyndromeHematologic Malignancies
Agios Pharmaceuticals, Inc. 46
Load More Results
97